Canada markets closed

Cocrystal Pharma, Inc. (COCP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.9200+0.0203 (+2.26%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.8997
Bid0.9100 x 900
Ask0.9224 x 800
Day's Range0.8900 - 0.9500
52 Week Range0.3900 - 3.0400
Avg. Volume3,637,577
Market Cap68.074M
Beta (5Y Monthly)-0.21
PE Ratio (TTM)N/A
EPS (TTM)-1.3900
Earnings DateMar. 30, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.67
  • GlobeNewswire

    Cocrystal Pharma to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

    – Live video webcast with Chairman and CEO, Dr. Gary Wilcox, on Monday, September 14th at 3:30 PM EDT –BOTHELL, WA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal, will present at H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 3:30 PM EDT.In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website here.A live video webcast of the presentation will be available on the IR Calendar page of the Investors section of the Company’s website ( The video webcast replay will be made available two hours following the event.About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, SARS-CoV-2 virus, hepatitis C viruses, and norovirus infections. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit Investor and Media Contact:JTC Team, LLC (833) 475-8247

  • GlobeNewswire

    The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Cocrystal Pharma, Inc. and/or BioZone Pharmaceuticals, Inc. – COCP

    NEWARK, N.J., Sept. 07, 2020 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. announces that the United States District Court for the District of New Jersey has approved the following announcement of a proposed class action settlement that would benefit purchasers of securities of Cocrystal Pharma, Inc. and/or BioZone Pharmaceuticals, Inc. (NASDAQ: COCP): SUMMARY NOTICE OF PENDENCY AND PROPOSED SECURITIES CLASS ACTION SETTLEMENTTO: ALL PERSONS WHO PURCHASED OR ACQUIRED THE PUBLICLY TRADED SECURITIES OF COCRYSTAL PHARMA, INC. AND/OR BIOZONE PHARMACEUTICALS, INC. BETWEEN SEPTEMBER 23, 2013 AND SEPTEMBER 7, 2018, BOTH DATES INCLUSIVE.YOU ARE HEREBY NOTIFIED, pursuant to an Order of the United States District Court for the District of New Jersey, that a hearing will be held on December 16, 2020, at 2:00 p.m. before the Honorable Kevin McNulty, United States District Judge of the District of New Jersey, 50 Walnut Street, Courtroom PO 04, Newark, New Jersey 07102 for the purpose of determining: (1) whether the proposed Settlement of the claims in the above-captioned Action for consideration including the sum of $1,265,000 should be approved by the Court as fair, reasonable, and adequate; (2) whether the proposed plan to distribute the Settlement proceeds is fair, reasonable, and adequate; (3) whether the application of Lead Counsel for attorneys’ fees of up to one-third of the Settlement Amount ($421,666.66) plus a proportionate share of interest accrued on the Settlement Amount, Lead Counsel’s reimbursement of litigation expenses incurred of not more than $65,000, and Awards to Plaintiffs of not more than $15,000 in total, should be approved; and (4) whether the Action should be dismissed with prejudice as set forth in the Stipulation and Agreement of Settlement, fully executed on August 17, 2020 (the “Settlement Stipulation”). The Court reserves the right to hold the Settlement Hearing telephonically or by other virtual means. The proposed Settlement would resolve the Action alleging that, in violation of the federal securities laws, Defendants (1) allegedly made misrepresentations and/or omissions of material fact in various public statements concerning an alleged scheme to inflate the price of securities of Cocrystal Pharma, Inc.’s (“Cocrystal” or the “Company”) predecessor, BioZone Pharmaceuticals, Inc. (“BioZone”) and an alleged undisclosed related party transaction, and (2) allegedly manipulated the market for BioZone securities. Defendants deny the allegations.If you purchased or acquired the publicly traded securities of Cocrystal and/or BioZone between September 23, 2013 and September 7, 2018, both dates inclusive (“Settlement Class Period”), your rights may be affected by this Settlement, including the release and extinguishment of claims you may possess relating to your ownership interest in Cocrystal securities. You may obtain copies of the detailed Notice of Pendency and Proposed Settlement of Securities Class Action (“Notice”) and the Proof of Claim and Release Form by writing to or calling the Claims Administrator: Cocrystal Pharma, Inc. Securities Litigation, c/o Strategic Claims Services, 600 N. Jackson St., Ste. 205, P.O. Box 230, Media, PA 19063; (Tel) (866) 274-4004; (Fax) (610) 565-7985; You can also download copies of the Notice and submit your Proof of Claim and Release Form online at If you are a member of the Settlement Class, in order to share in the distribution of the Net Settlement Fund, you must submit a Proof of Claim and Release Form electronically or postmarked no later than November 16, 2020 to the Claims Administrator, establishing that you are entitled to recovery. Unless you submit a written exclusion request, you will be bound by any judgment rendered in the Action whether or not you make a claim. If you are a Settlement Class Member and desire to be excluded from the Settlement Class, you must submit to the Claims Administrator a request for exclusion so that it is received no later than November 25, 2020, in the manner and form explained in the detailed Notice. All members of the Settlement Class who have not requested exclusion from the Settlement Class will be bound by any judgment entered in the Action pursuant to the Settlement Stipulation.Any objection by a Settlement Class Member to the Settlement, Plan of Allocation, Lead Counsel’s requests for an award to Lead Counsel of attorneys’ fees and reimbursement of expenses and Awards to Plaintiffs must be in the manner and form explained in the detailed Notice and received no later than November 25, 2020, by each of the following:Clerk of the Court United States District Court District of New Jersey Martin Luther King Building & U.S. Courthouse 50 Walnut Street Newark, NJ 07102LEAD COUNSEL: THE ROSEN LAW FIRM, P.A. Phillip Kim 275 Madison Avenue, 40th Floor New York, NY 10016 COUNSEL FOR DEFENDANTS COCRYSTAL PHARMA, INC., GARY WILCOX, JEFFREY MECKLER, GERALD MCGUIRE, JAMES MARTIN, AND CURTIS DALE: PERKINS COIE LLP Ronald L. Berenstain 1201 Third Avenue, Suite 4900 Seattle, WA  98101COUNSEL FOR DEFENDANT PHILLIP FROST MORVILLO ABRAMOWITZ GRAND IASON & ANELLO P.C. Robert J. Anello 565 Fifth Avenue New York, NY 10017 COUNSEL FOR DEFENDANT BARRY HONIG: WILSON SONSINI GOODRICH & ROSATI Michael Sommer 1301 Avenue of the Americas, 40th Floor New York, NY 10019 COUNSEL FOR DEFENDANTS JOHN STETSON AND STETSON CAPITAL INVESTMENTS, INC.: MILBANK, LLP Adam Fee 55 Hudson Yards New York, NY 10001 COUNSEL FOR DEFENDANTS MARK GROUSSMAN AND MELECHDAVID, INC.: BAKER MCKENZIE LLP Perrie Weiner 1901 Avenue of the Stars, Suite 950 Los Angeles, CA 90067COUNSEL FOR DEFENDANTS JOHN O’ROURKE III AND ATG CAPITAL LLC ORRICK, HERRINGTON & SUTCLIFFE LLP Randy Luskey 405 Howard Street San Francisco, CA 94105 COUNSEL FOR DEFENDANT JOHN FORD: CHIESA SHAHINIAN & GIANTOMASI P.C. A. Ross Pearlson One Boland Drive West Orange, NJ 07052COUNSEL FOR DEFENDANTS MICHAEL BRAUSER AND GRANDER HOLDINGS, INC. RICHARD AND RICHARD, P.A. Dennis Richard Melissa L. Mackiewicz 825 Brickell Bay Drive Tower III, Suite 1748 Miami, FL 33131 Elliot Maza 550 Sylvan Avenue, Suite 102 Englewood Cliffs, NJ 07632Brian Keller 5058 Nortonville Way Antioch CA 94531 If you have any questions about the Settlement, you may call or write to Lead Counsel:THE ROSEN LAW FIRM, P.A. Phillip Kim 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 pkim@rosenlegal.comPLEASE DO NOT CONTACT THE COURT OR THE CLERK’S OFFICE REGARDING THIS NOTICE.Dated: August 18, 2020        BY ORDER OF THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW JERSEY

  • GlobeNewswire

    Cocrystal Pharma Announces Closing of $17.2 Million Bought Deal Including Partial Exercise of Underwriter's Option to Purchase Additional Shares

    BOTHELL, WA, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today the closing of its previously announced underwritten public offering of 16,422,813 shares of common stock of the Company, including the partial exercise by the underwriter of the option to purchase an additional 2,137,098 shares of common stock, at a price to the public of $1.05 per share. H.C. Wainwright & Co. acted as the sole book-running manager for the offering.The Company had granted to the underwriter a 30-day option to purchase up to an additional 2,142,857 shares of common stock at the public offering price, less underwriting discounts and commissions, of which the option to purchase an additional 2,137,098 shares of common stock has been exercised. The gross proceeds to Cocrystal, before deducting underwriting discounts and commissions and offering expenses, including the partial exercise of the underwriter's option to purchase 2,137,098 additional shares of common stock, are approximately $17.2 million. The Company intends to use the net proceeds from this offering for the expansion of our COVID-19 and Influenza treatment development programs and general corporate purposes and working capital.The shares of common stock were offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-237738) originally filed with the Securities and Exchange Commission (the "SEC") on April 17, 2020, and declared effective by the SEC on May 13, 2020. The offering of the shares of common stock was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC's website at and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (646) 975-6996 or e-mail at press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, hepatitis C viruses, coronaviruses and noroviruses.Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to our intended use of proceeds and other statements that are not historical fact. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, risks arising from our reliance on continuing collaboration with Merck Sharp & Dohme Corp. under the collaboration agreement entered into last year, market and other conditions, any impact from the COVID -19 pandemic and its impact on the economy, the availability of products manufactured by third parties, the future results of preclinical and clinical studies, general risks arising from clinical trials, receipt of regulatory approvals, our ability to find and enter into agreements with suitable collaboration partners, unanticipated litigation and other expenses and factors that affect the capital markets in general and early stage biotechnology companies specifically. Further information on our risk factors is contained in our filings with the SEC, including our Prospectus Supplement dated August 26, 2020, our Annual Report on Form 10-K for the year ended December 31, 2019 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.Investor and Media Contact: JTC Team, LLC (833) 475-8247